Across TCGA pan-cancer cohorts, LEPROT mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LEPROT data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher LEPROT mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LEPROT expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

GBM, LUAD, and LSCC are the cancer types where LEPROT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.535	0.810	.012	8	view →
LUAD	DFS	Median	III,IV	0.899	0.418	.035	8	view →
LSCC	OS	Median	III,IV	1.000	0.383	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: LEPROT tumor-vs-normal RNA expression · all LEPROT data types